Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

GE Carlsson, A Möller, C Blomstrand, T Ueda… - Cerebrovascular …, 2003 - karger.com
Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary
heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history
of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol
Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-
controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who
previously experienced a stroke or transient ischaemic attack, but who have no known CHD …

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study (vol 16, pg 389, 2003)

WM Clark, A Davalos, LB Goldstein… - Cerebrovascular …, 2004 - research.rug.nl
Design and baseline characteristics of the stroke prevention by aggressive reduction in
cholesterol levels (SPARCL) study (vol 16, pg 389, 2003) — the University of Groningen
research portal … Design and baseline characteristics of the stroke prevention by
aggressive reduction in cholesterol levels (SPARCL) study (vol 16, pg 389, 2003) … the
University of Groningen research portal data protection policy …
以上显示的是最相近的搜索结果。 查看全部搜索结果